FAQ

SM-88 is an oral investigational modified proprietary tyrosine derivative that is believed to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events. SM-88 is an investigational therapy that is not approved for any indication in any disease.

At this time, we do not have any ongoing trials evaluating our lead cancer metabolism-based therapy (CMBT), SM-88, as a potential treatment for patients with pancreatic cancer. For more information, please visit us at TYMEtrials.com.

Yes, we do have an ongoing trial evaluating our lead cancer metabolism-based therapy (CMBT), SM-88, as a potential treatment for patients with Ewing’s and high-risk sarcoma. For more information, please visit us at TYMEtrials.com.

Our clinical trial evaluating SM-88 as a potential treatment for patients with recurring prostate cancer is now completed. The purpose of this study was to evaluate the safety, pharmacokinetics, and efficacy of SM-88 in patients with prostate cancer that has not become metastatic.

The final data were presented at the European Society of Medical Oncology Congress (ESMO) held on September 27- October 1, 2019 in Barcelona, Spain. For more information, please visit us at TYMEtrials.com.

At this time, we do not have information to provide for the opening of trials for other cancers. Please visit TYMEtrials.com for any updates for the potential opening of new cancer trials.

Please visit TYMEtrials.com for more information.

SM-88 is an investigational therapy that is not approved for any indication and is not available for purchase.

Overview of SM-88 can be found at tymeinc.com/pipeline/sm-88-overview/